← Back to Search

Other

Sequential Therapies for Breast Cancer

Phase < 1
Recruiting
Led By Aixa Soyano, MD
Research Sponsored by H. Lee Moffitt Cancer Center and Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
A negative pregnancy test for pre-menopausal women of childbearing potential
ECOG performance status 0-1
Must not have
Documented brain metastasis or active or newly diagnosed CNS metastases
Treatment with any investigational compound within 30 days prior to the first dose of study drugs or during this study
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 18 months
Awards & highlights

Summary

This trial aims to test a new way of giving approved drugs to treat metastatic breast cancer to see if it could be more effective than the current method.

Who is the study for?
This trial is for individuals with metastatic breast cancer. Participants should be suitable to receive the study drugs, which are all approved treatments. Specific eligibility criteria were not provided, so interested individuals should contact the study team for more details.
What is being tested?
The trial is testing a new treatment strategy using existing drugs: Abemaciclib, Sacituzumab govitecan, Trastuzumab deruxtecan, Xeloda (capecitabine), Taxotere (docetaxel), Cytoxan (cyclophosphamide), Fulvestrant and Ribociclib. The goal is to see if administering these drugs sequentially based on evolutionary dynamics can improve outcomes in metastatic breast cancer.
What are the potential side effects?
Potential side effects include nausea, fatigue, hair loss from chemotherapy agents like Taxotere and Cytoxan; diarrhea and hand-foot syndrome from Xeloda; low blood cell counts from most of these medications; liver issues from Abemaciclib; allergic reactions or infusion-related symptoms from monoclonal antibodies like Trastuzumab deruxtecan.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am not pregnant.
Select...
I am fully active or can carry out light work.
Select...
My breast cancer is hormone positive and HER2 negative, confirmed by tests.
Select...
My breast cancer is hormone positive and was treated with hormone therapy.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have brain metastasis or newly diagnosed CNS metastases.
Select...
I haven't taken any experimental drugs in the last 30 days.
Select...
I do not have any severe illnesses or social situations that would stop me from following the study's requirements.
Select...
My cancer has spread to vital organs and poses an immediate risk to my life.
Select...
I have tested positive for HIV or have AIDS.
Select...
I have had allergic reactions to similar medications in the past.
Select...
I have been treated with Fulvestrant for my breast cancer.
Select...
I do not have active infections like TB, hepatitis B, or hepatitis C.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility of Sequential Therapy
Secondary outcome measures
No Evidence of Disease (NED)
Safety and Tolerability

Trial Design

1Treatment groups
Experimental Treatment
Group I: Sequential therapyExperimental Treatment8 Interventions
In this study sequential therapies will be administered. Strike 1: Cytoxan/Taxotere/GM-CSF Strike 2: Sacituzumab govitecan or trastuzumab deruxtecan Strike 3: Capecitabine Strike 4: Fulvestrant + CDK 4/6 inhibitor (ribociclib or abemaciclib)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Trastuzumab deruxtecan
2022
Completed Phase 2
~580
Sacituzumab govitecan
2017
Completed Phase 3
~530
Taxotere
2006
Completed Phase 4
~4940
Cytoxan
2007
Completed Phase 3
~1460
Fulvestrant
2011
Completed Phase 3
~3890
Xeloda
2002
Completed Phase 4
~4930
Ribociclib
2018
Completed Phase 3
~2420
Abemaciclib
2019
Completed Phase 2
~1800

Find a Location

Who is running the clinical trial?

H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
558 Previous Clinical Trials
144,525 Total Patients Enrolled
42 Trials studying Breast Cancer
5,796 Patients Enrolled for Breast Cancer
Aixa Soyano, MDPrincipal InvestigatorMoffitt Cancer Center
~10 spots leftby Apr 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top